Eckert & Ziegler with Sales Growth in the First Quarter of 2022
Berlin, 12 May 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 13% to EUR 49.9 million in the first quarter of 2022. The net profit of EUR 6.7 million or EUR 0.32 per share was below the previous year's quarter. This earnings gap compared to the previous year is due to a one-off effect of around EUR 6.8 million in the first quarter of 2021, in which the Group sold its tumour irradiation business at a profit. Despite the pandemic and the war in Ukraine, the Q1 figures reflect a stable start to the year.
Revenue in the Medical segment was EUR 20.1 million in the first quarter, EUR 1.2 million or 5% below the previous year's figure. Taking into account the loss of sales of EUR 1.1 million due to the deconsolidation of the tumour irradiation business, the sales level was maintained compared to the previous year.
The Isotope Products segment achieved revenue of EUR 29.8 million, which is EUR 7.0 million or about 31% higher than in the first three months of 2021, due to rising oil and gas prices and an associated exceptional demand in radiometric components for energy companies. Around EUR 1.9 million of the increase is attributable to the acquisition of the Argentinian company Tecnonuclear SA in January 2022.
The results of the first quarter of 2022 are in line with the expectations of the Executive Board. The forecast for the 2022 financial year published in March remains unaffected. The Executive Board continues to expect sales of around EUR 200 million and a net profit of around EUR 38 million. The forecast is subject to the assumption that the developments in Ukraine do not result in any major disruptions.
The complete quarterly report can be viewed here:
www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz122e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 900 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
12.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language:EnglishCompany:Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
GermanyPhone:+49 30 941084-138Fax:+49 30 941084-112E-mail:karolin.riehle@ezag.deInternet:www.ezag.deISIN:DE0005659700WKN:565970Indices:SDAXListed:Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate ExchangeEQS News ID:1349897
End of NewsDGAP News Service
